D. Western Therapeutics Institute Inc

Research D. Western Therapeutics Institute Inc (6DW) on Bullrun: market cap EUR 22.26M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 22.26M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025JPY 387.62M-JPY 632.09M-JPY 496.54M90.0%-13.19JPY 1.71BJPY 605.18MJPY 1.44B
FY2024JPY 471.58M-JPY 1.29B-JPY 1.31B90.1%-36.74JPY 1.13BJPY 797.98MJPY 733.87M
FY2023JPY 428.36M-JPY 812.41M-JPY 601.76M91.4%-25.56JPY 1.87BJPY 885.12MJPY 1.28B
FY2022JPY 448.10M-JPY 429.69M-JPY 364.58M93.8%-14.5JPY 2.33BJPY 967.69MJPY 1.86B

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-14EUR 22.26Mn/an/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 EUR.

About D. Western Therapeutics Institute Inc

D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. It offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is D. Western Therapeutics Institute Inc's market cap?

D. Western Therapeutics Institute Inc's market capitalization is EUR 22.26M.

What does D. Western Therapeutics Institute Inc do?

D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. It offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining.